In the inTandem phase 3 trials, the rates of documented hypoglycemia were evaluated as plasma glucose ≤70 and ≤55 mg/dL.11–13 To further examine the incidence of hypoglycemia when sotagliflozin is used in combination with optimized insulin treatment, we conducted an exploratory post hoc analysis of pooled data from inTandem1 and 2 to compare the rate of hypoglycemia at each week 52 HbA1c value among patients receiving placebo and sotagliflozin over 1 year. The gene discussed is INS; the disease is Hypoglycemia.